Abstract

significant repigmentation in vitiligo was reported with tofacitinib citrate treatment (Craiglow et al., 2015). A case of reversal of alopecia areata has been observed with baricitinib treatment (Jabbari et al., 2015). In summary, we demonstrate a substantial benefit from ruxolitinib therapy in a case of chilblain LE.Our observation supports the idea that JAK/STAT inhibition provides a promising therapeutic approach for the treatment of cutaneous autoimmune diseases, particularly LE.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.